Crucial Deadline Looms for Savara Investors in Class Action Lawsuit Over Alleged Molgradex Misstatements

A critical alert has been issued to investors of Savara, Inc. (NASDAQ: SVRA) regarding a pending class action lawsuit. Renowned law firm Faruqi & Faruqi, LLP, is reminding affected shareholders of the fast-approaching deadline to apply for lead plaintiff status, a pivotal step in seeking justice and recovery for alleged financial losses.

The lawsuit centers on allegations that Savara, Inc.

made materially false and misleading statements to the investing public concerning its experimental drug, Molgradex, specifically related to the Phase 3 IMPALA trial results for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). These statements, made during the period between October 29, 2018, and November 19, 2019, are now under intense scrutiny.

According to the complaint, Savara is accused of misrepresenting the "Molgradex Treatment Effect" within the IMPALA trial data.

Specifically, the company allegedly stated that the treatment effect was statistically significant, a claim later challenged and found to be potentially misleading. Such misrepresentations can significantly impact investor decisions, leading to unforeseen financial detriment when the truth is revealed.

Investors who purchased Savara securities during the defined class period—October 29, 2018, to November 19, 2019—and suffered financial harm are encouraged to take immediate action.

The deadline to move the Court for appointment as lead plaintiff is rapidly approaching: February 10, 2020.

Becoming a lead plaintiff is a vital role, allowing an individual or small group of investors to represent the interests of all class members in the litigation. This position offers a unique opportunity to directly influence the direction of the lawsuit and ensure that the collective voice of affected shareholders is heard.

Faruqi & Faruqi, LLP, a firm with a strong track record in prosecuting securities class actions and recovering significant damages for investors, is actively investigating these claims and urging affected parties to come forward.

If you are a Savara investor who acquired shares during this period and experienced losses, it is imperative to contact a qualified legal professional to understand your rights and the implications of this lawsuit.

Taking action before the February 10th deadline is crucial to protecting your interests and potentially recovering the losses you may have incurred due to these alleged deceptive practices.